AimMax Therapeutix

AimMax Therapeutix is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, specializing in the development of innovative and improved therapeutic products. The company primarily utilizes the FDA's 505(b)(2) regulatory pathway, which allows for the optimization of existing drugs to enhance efficacy, safety, and patient compliance. Their diverse pipeline targets significant medical needs in ophthalmology, pain management, and cardiovascular diseases. AimMax's lead candidate, AM-102, is a Phase 3 program for the treatment of glaucoma and ocular hypertension. By focusing on value-added medicines with established safety profiles, the company aims to deliver high-quality treatments with reduced development risk and accelerated timelines.